Skip to main content
Erschienen in: Journal of Neurology 6/2020

25.02.2020 | Original Communication

Symptomatic and asymptomatic intracranial atherosclerotic stenosis: 3 years’ prospective study

verfasst von: Urs Fischer, Kety Hsieh-Meister, Frauke Kellner-Weldon, Aikaterini Galimanis, Xin Yan, Johannes Kaesmacher, Marwan El-Koussy, Simon Jung, Marcel Arnold, Patrik Michel, Roland Wiest, Heinrich P. Mattle, Jan Gralla, Mirjam R. Heldner

Erschienen in: Journal of Neurology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Intracranial stenoses can cause TIA/ischaemic stroke. The purpose of this study was to assess vascular risk factors, clinical and imaging findings and outcome in Caucasians with intracranial stenosis under best prevention management.

Methods

In this prospective observational study (from 05/2012, to last follow-up 06/2017) we compared vascular risk factors, imaging findings and long-term outcome in Swiss patients with symptomatic versus asymptomatic intracranial atherosclerotic stenoses on best prevention management.

Results

62 patients were included [35.5% women, median age 68.3 years], 33 (53.2%) with symptomatic intracranial stenoses. Vascular risk factors (p = 0.635) and frequency of anterior circulation stenoses (66.7% vs. 55.2%; p = 0.354) did not differ between symptomatic and asymptomatic patients, but CT/MR-perfusion deficits in the territory of the stenosis (81.8% vs. 51.7%; p = 0.011) were more common in symptomatic patients. Outcome in symptomatic and asymptomatic patients at last follow-up was similar (mRS 0–1:66.7% vs. 75%;adjp = 0.937, mRS adjp-shift = 0.354, survival:100% vs. 96.4%;adjp = 0.979). However, during 59,417 patient follow-up days, symptomatic patients experienced more cerebrovascular events (ischaemic stroke or TIA) [37.5% vs. 7.1%;adjHR 7.58;adjp = 0.012], mainly in the territory of the stenosis [31.3% vs. 3.6%;adjHR 12.69;adjp = 0.019], more vascular events (i.e. ischaemic stroke/TIA/TNA and acute coronary/peripheral vascular events) [62.5% vs. 14.3%;adjHR 6.37;adjp = 0.001]) and more multiple vascular events (p-trend = 0.006; ≥ 2:37.5% vs. 10.7%;adj OR 5.37;adjp = 0.022) than asymptomatic patients.

Conclusions

Despite best prevention management, one in three patients with a symptomatic intracranial stenosis suffered a cerebrovascular event, three in five a vascular event and two in five ≥ 2 vascular events. There is an unmet need for more rigorous and effective preventive strategies in patients with symptomatic intracranial stenoses.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat GBD 2015 Mortality and Causes of Death Collaborators (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet 388:1459–1544. https://doi.org/10.1016/S0140-6736(16)31012-1 CrossRef GBD 2015 Mortality and Causes of Death Collaborators (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet 388:1459–1544. https://​doi.​org/​10.​1016/​S0140-6736(16)31012-1 CrossRef
5.
Zurück zum Zitat Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549–559. https://doi.org/10.1056/NEJMoa061894 CrossRefPubMed Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549–559. https://​doi.​org/​10.​1056/​NEJMoa061894 CrossRefPubMed
6.
Zurück zum Zitat Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol, Trialists’ (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278. https://doi.org/10.1016/S0140-6736(05)67394-1TreatmentCrossRefPubMed Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol, Trialists’ (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278. https://​doi.​org/​10.​1016/​S0140-6736(05)67394-1TreatmentCrossRefPubMed
7.
Zurück zum Zitat Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849–1860. https://doi.org/10.1016/S0140-6736(09)60503-1 CrossRef Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849–1860. https://​doi.​org/​10.​1016/​S0140-6736(09)60503-1 CrossRef
10.
Zurück zum Zitat Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL (2009) Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American heart association/American stroke association stroke council; council on cardiovascular surgery and anesthesia; council on cardiovascular radiology and intervention; council on cardiovascular nursing; and the interdisciplinary council on peripheral vascular disease. Stroke 40:2276–2293. https://doi.org/10.1161/STROKEAHA.108.192218 CrossRefPubMed Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL (2009) Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American heart association/American stroke association stroke council; council on cardiovascular surgery and anesthesia; council on cardiovascular radiology and intervention; council on cardiovascular nursing; and the interdisciplinary council on peripheral vascular disease. Stroke 40:2276–2293. https://​doi.​org/​10.​1161/​STROKEAHA.​108.​192218 CrossRefPubMed
11.
Zurück zum Zitat Hathout GM, Fink JR, Saden SM, Grand EG (2005) Sonographic NASCET index: a new doppler parameter for assessment of internal carotid artery stenosis. Am J Neuroradiol 26:68–75PubMed Hathout GM, Fink JR, Saden SM, Grand EG (2005) Sonographic NASCET index: a new doppler parameter for assessment of internal carotid artery stenosis. Am J Neuroradiol 26:68–75PubMed
19.
Zurück zum Zitat Zaidat OO, Fitzsimmons BF, Woodward BK, Wang Z, Killer-Oberpfalzer M, Wakhloo A, Gupta R, Kirshner H, Megerian JT, Lesko J, Pitzer P, Ramos J, Castonguay AC, Barnwell S, Smith WS, Gress DR, for the VISSIT Trial Investigators (2015) Effect of a balloon expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA 313:1240–1248. https://doi.org/10.1001/jama.2015.1693 CrossRefPubMed Zaidat OO, Fitzsimmons BF, Woodward BK, Wang Z, Killer-Oberpfalzer M, Wakhloo A, Gupta R, Kirshner H, Megerian JT, Lesko J, Pitzer P, Ramos J, Castonguay AC, Barnwell S, Smith WS, Gress DR, for the VISSIT Trial Investigators (2015) Effect of a balloon expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA 313:1240–1248. https://​doi.​org/​10.​1001/​jama.​2015.​1693 CrossRefPubMed
20.
Zurück zum Zitat Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG, for the Warfarin–Aspirin Symptomatic Intracranial Disease Trial Investigators (2005) Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352:1305–1316. https://doi.org/10.1056/NEJMoa043033 CrossRefPubMed Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG, for the Warfarin–Aspirin Symptomatic Intracranial Disease Trial Investigators (2005) Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352:1305–1316. https://​doi.​org/​10.​1056/​NEJMoa043033 CrossRefPubMed
22.
Zurück zum Zitat Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ (2014) Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 64:485–494. https://doi.org/10.1016/j.jacc.2014.02.615 CrossRefPubMedPubMedCentral Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ (2014) Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 64:485–494. https://​doi.​org/​10.​1016/​j.​jacc.​2014.​02.​615 CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722. https://doi.org/10.1056/NEJMoa1615664 CrossRef Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722. https://​doi.​org/​10.​1056/​NEJMoa1615664 CrossRef
28.
Zurück zum Zitat Planas-Ballvé A, Crespo AM, Aguilar LM, Hernández-Pérez M, Canento T, Dorado L, Alzamora MT, Torán P, Pera G, Muñoz-Ortiz L, Arenillas JF, Castañón M, Dávalos A, Millán M, López-Cancio E (2019) The Barcelona-Asymptomatic Intracranial Atherosclerosis study: subclinical intracranial atherosclerosis as predictor of long-term vascular events. Atherosclerosis 282:132–136. https://doi.org/10.1016/j.atherosclerosis.2019.01.022 CrossRefPubMed Planas-Ballvé A, Crespo AM, Aguilar LM, Hernández-Pérez M, Canento T, Dorado L, Alzamora MT, Torán P, Pera G, Muñoz-Ortiz L, Arenillas JF, Castañón M, Dávalos A, Millán M, López-Cancio E (2019) The Barcelona-Asymptomatic Intracranial Atherosclerosis study: subclinical intracranial atherosclerosis as predictor of long-term vascular events. Atherosclerosis 282:132–136. https://​doi.​org/​10.​1016/​j.​atherosclerosis.​2019.​01.​022 CrossRefPubMed
29.
Zurück zum Zitat Maier IL, Karch A, Lipke C, Behme D, Mpotsaris A, Kabbasch C, Liebig T, Faymonville A, Reich A, Nikoubashman O, Buhk JH, von Schoenfeld P, Weber W, Mikolajczyk RT, Bähr M, Knauth M, Kallenberg K, Liman J (2018) Transluminal angioplasty and stenting versus conservative treatment in patients with symptomatic basilar artery stenosis: perspective for future clinical trials. Clin Neuroradiol 28:33–38. https://doi.org/10.1007/s00062-016-0528-x CrossRefPubMed Maier IL, Karch A, Lipke C, Behme D, Mpotsaris A, Kabbasch C, Liebig T, Faymonville A, Reich A, Nikoubashman O, Buhk JH, von Schoenfeld P, Weber W, Mikolajczyk RT, Bähr M, Knauth M, Kallenberg K, Liman J (2018) Transluminal angioplasty and stenting versus conservative treatment in patients with symptomatic basilar artery stenosis: perspective for future clinical trials. Clin Neuroradiol 28:33–38. https://​doi.​org/​10.​1007/​s00062-016-0528-x CrossRefPubMed
30.
32.
Metadaten
Titel
Symptomatic and asymptomatic intracranial atherosclerotic stenosis: 3 years’ prospective study
verfasst von
Urs Fischer
Kety Hsieh-Meister
Frauke Kellner-Weldon
Aikaterini Galimanis
Xin Yan
Johannes Kaesmacher
Marwan El-Koussy
Simon Jung
Marcel Arnold
Patrik Michel
Roland Wiest
Heinrich P. Mattle
Jan Gralla
Mirjam R. Heldner
Publikationsdatum
25.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 6/2020
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-020-09750-2

Weitere Artikel der Ausgabe 6/2020

Journal of Neurology 6/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.